LETTER TO THE EDITOR
Comment on: Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004–2019. Emerging therapeutic options for sickle cell anemia: Enhancing the current predominant treatment
Sameer Abdul Rauf,
Sameer Abdul Rauf
Department of Internal Medicine, Liaquat National Medical College, Karachi, Pakistan
Search for more papers by this author Tooba Hussain,
Tooba Hussain
Department of Internal Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan
Search for more papers by this author Hussain Haider Shah,
Corresponding Author
Hussain Haider Shah
Department of Internal Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan
Correspondence
Hussain Haider Shah, Department of Internal Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan.
Email: [email protected]
Search for more papers by this author Muhammad Sheheryar Hussain,
Muhammad Sheheryar Hussain
Department of Internal Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan
Search for more papers by this author Radeyah Waseem,
Radeyah Waseem
Department of Internal Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan
Search for more papers by this author
Sameer Abdul Rauf,
Sameer Abdul Rauf
Department of Internal Medicine, Liaquat National Medical College, Karachi, Pakistan
Search for more papers by this author Tooba Hussain,
Tooba Hussain
Department of Internal Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan
Search for more papers by this author Hussain Haider Shah,
Corresponding Author
Hussain Haider Shah
Department of Internal Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan
Correspondence
Hussain Haider Shah, Department of Internal Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan.
Email: [email protected]
Search for more papers by this author Muhammad Sheheryar Hussain,
Muhammad Sheheryar Hussain
Department of Internal Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan
Search for more papers by this author Radeyah Waseem,
Radeyah Waseem
Department of Internal Medicine, Dow University of Health Sciences Karachi, Karachi, Pakistan
Search for more papers by this author
First published: 30 May 2023
No abstract is available for this article.
REFERENCES
- 1Tang AY, Zhou M, Maillis AN, Lai KW, Lane PA, Snyder AB. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004–2019. Pediatr Blood Cancer. 2023; 70(3):e30152. 10.1002/pbc.30152
- 2Ali MA, Ahmad A, Chaudry H, et al. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp. Hematol. 2020; 92: 11-18.e1. 10.1016/j.exphem.2020.08.008
- 3Kanter J, Walters MC, Krishnamurti L, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N. Engl. J. Med. 2022; 386(7): 617-628. 10.1056/NEJMoa2117175
